BioRegenx, Inc.
BRGX
$0.01
$0.0041.11%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.56% | -26.79% | -20.09% | -31.41% | 154.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.56% | -26.79% | -20.09% | -31.41% | 154.50% |
| Cost of Revenue | -50.02% | -52.27% | -34.41% | -38.02% | 174.65% |
| Gross Profit | -12.03% | -13.34% | -13.02% | -28.25% | 145.66% |
| SG&A Expenses | -42.20% | -63.15% | -48.76% | 23.86% | 126.64% |
| Depreciation & Amortization | 0.00% | -- | -- | -- | 9,427.12% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.83% | -50.30% | -35.04% | 30.36% | 150.84% |
| Operating Income | 48.21% | 59.83% | 41.88% | -92.16% | -148.86% |
| Income Before Tax | -285.45% | -173.53% | -209.20% | -540.39% | -182.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -285.45% | -173.53% | -209.20% | -540.39% | -182.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -285.45% | -173.53% | -209.20% | -540.39% | -182.47% |
| EBIT | 48.21% | 59.83% | 41.88% | -92.16% | -148.86% |
| EBITDA | 41.04% | 73.24% | 66.68% | -27.24% | -61.34% |
| EPS Basic | -219.67% | -102.04% | -121.28% | -331.58% | -69.44% |
| Normalized Basic EPS | 52.63% | 66.67% | 55.17% | -47.06% | -72.73% |
| EPS Diluted | -219.67% | -102.04% | -121.28% | -331.58% | -69.44% |
| Normalized Diluted EPS | 52.63% | 66.67% | 55.17% | -47.06% | -72.73% |
| Average Basic Shares Outstanding | 13.95% | 26.34% | 34.77% | 35.17% | 13.78% |
| Average Diluted Shares Outstanding | 13.95% | 26.34% | 34.77% | 35.17% | 13.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |